

## ASX/Media Release

### RESULTS OF ANNUAL GENERAL MEETING

**SYDNEY, AUSTRALIA – 24 October 2023** – [Immutep Limited](#) (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) advises that the results of its Annual General Meeting (AGM) are set out in the attached document in accordance with section 251AA(2) of the *Corporations Act 2001* (Cth) and Listing Rule 3.13.2.

Resolution 7 was withdrawn as the Company’s market cap remained above \$300m on the date of the AGM and hence it was ineligible for the additional 10% placement capacity, as explained in the Company’s Notice of Meeting.

Please be advised that all resolutions in the Company’s 2023 Notice of Annual General Meeting were passed by the requisite majorities at today’s AGM.

All resolutions were passed and decided by way of poll.

#### **About Immutep**

Immutep is a clinical stage biotechnology company leading the development of LAG-3 related immunotherapy products for the treatment of cancer and autoimmune disease. The Company is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.

Immutep’s lead product candidate is efitlagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3lg), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer in multiple clinical trials. The Company is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 product candidates, including antibodies for immune response modulation, are licensed to and being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website [www.immutep.com](http://www.immutep.com) or by contacting:

#### **Australian Investors/Media:**

Catherine Strong, Citadel-MAGNUS  
+61 (0)406 759 268; [cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)

#### **U.S. Media:**

Tim McCarthy, LifeSci Advisors  
+1 (917) 679 9282; [tim@lifesciadvisors.com](mailto:tim@lifesciadvisors.com)

This announcement was authorised for release by Deanne Miller, COO & Company Secretary of Immutep Limited.

**Immutep Limited**  
**Annual General Meeting**  
**Tuesday, 24 October 2023**  
**Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried	
1. Adoption of Remuneration Report	Ordinary	454,561,560 97.15%	10,421,562 2.23%	2,937,570 0.63%	3,599,800	458,884,275 97.72%	10,704,424 2.28%	3,599,800	Carried	No
2. Re-election of Director - Mr Russell Howard	Ordinary	478,881,648 98.66%	3,625,412 0.75%	2,882,131 0.59%	2,424,772	483,148,924 99.20%	3,908,274 0.80%	2,424,772	Carried	NA
3. Election of Director - Ms Elisabeth (Lis) Boyce	Ordinary	479,166,959 98.74%	3,219,314 0.66%	2,891,978 0.60%	2,539,712	483,726,944 99.34%	3,219,314 0.66%	2,539,712	Carried	NA
4. Approval of grant of performance rights to Dr Russell Howard	Ordinary	475,345,796 97.91%	7,176,795 1.48%	2,956,010 0.61%	1,227,745	479,666,951 98.46%	7,479,657 1.54%	1,227,745	Carried	NA
5. Approval of grant of performance rights to Ms Elisabeth (Lis) Boyce	Ordinary	476,310,817 97.89%	7,311,112 1.50%	2,963,829 0.61%	1,233,735	480,821,426 98.50%	7,331,112 1.50%	1,334,962	Carried	NA
6. Ratification of prior issue of Shares	Ordinary	240,066,721 94.51%	10,948,220 4.31%	3,005,025 1.18%	221,224,249	244,618,526 95.67%	11,069,447 4.33%	221,224,249	Carried	NA
7. Approval of additional 10% placement capacity	Special	307,628,976 63.30%	175,269,308 36.07%	3,051,990 0.63%	1,877,979	311,466,828 63.99%	175,289,308 36.01%	2,740,124	Withdrawn	NA

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.